Kura Oncology Stock Surges as Darlifarib + Cabozantinib Shows Strong Results in Tough Kidney Cancer Cases
Kura Oncology’s combo drug shrank kidney tumors in early trial, controlled cancer in most patients, stock jumped.
/ 3 items
#KURA↓
FDA Approves Kura's Ziftomenib (Komzifti) for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible NPM1 Mutation
The FDA has approved Komzifti for adults facing difficult-to-treat AML linked to a specific NPM1 gene change.
Kura Oncology Shares Jump 6% After $30M Milestone Payment for Cancer Drug Trial
Kura Oncology stock rises 6% in premarket trading after receiving $30 million milestone payment from Kyowa Kirin for Phase 3 cancer drug trial advancement.